This site uses cookies. By using this site you agree to receiving cookies. View Policy.
50% of vaccines are wasted, mainly due to poor refrigeration. Stablepharma's invention is designed to deliver a disruptive solution that can eliminate waste & supply life-saving vaccines to all without refrigeration. Proof of Concept has been achieved & investment is now sought for commercialisation.
'Every 20 seconds a child dies from a vaccine-preventable disease'
Gates Foundation
Problem: Vaccines are perishable, requiring constant & precise refrigeration from the manufacturer to the patient, be it in a UK Hospital or a clinic in Africa. The WHO estimates that c 50% of all vaccines are wasted in spite of c $400m p.a. spent on the global Cold Chain
Solution: this patented invention will allow vaccines to be transported & stored for years without refrigeration whilst complying with the protocols set by the WHO. It’s an important breakthrough that can save many lives.
Stablevax comprises approved vaccines which are dried from a solution of stabilising sugar into a special sponge stored in a normal syringe. They are pre-dosed and safe, to use you just add water. Stable vaccines will be manufactured at c. the same price as current products
£600k of equity funding enabled completion of R&D to the Proof of Concept milestone independently verified by the National Institute of Biological Standards and Controls (NHS & WHO-accredited Laboratory)
The current project plan involves the Tetanus vaccine processed through Clinical Trials in Humans, this achievement will significantly enhance the value of the invention and allow us to set up pilot scale production as the last step to commercialisation to enter the c. $36 bn human vaccine market and exploit this truly disruptive invention